New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
05:25 EDTFMSFresenius Medical upgraded to Buy from Neutral at UBS
News For FMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
10:01 EDTFMSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:09 EDTFMSFresenius Medical downgraded to Equal Weight from Overweight at Barclays
06:40 EDTFMSFresenius Medical downgraded to Neutral from Buy at UBS
UBS downgraded Fresenius Medical to Neutral citing limited upside to shares.
January 15, 2015
09:17 EDTFMSFlamel Technologies weakness creates buying opportunity, says SunTrust
Subscribe for More Information
08:47 EDTFMSFlamel Technologies price target lowered to $17 from $22 at Roth Capital
Roth Capital cut its price target on Flamel (FLML) after the FDA approved Fresenius Kabi's (FMS) New Drug Application for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. Roth expects eostigmine to become a two player market, but adds that price increases by Flamel could mitigate the negative impacts on Flamel's growth. The firm keeps a Buy rating on Flamel.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use